A MOLECULAR PREDICTOR OF RESPONSE TO BEVACIZUMAB BASED ON ANALYSIS OF RTOG 0825, A PHASE III TRIAL COMPARING CHEMORADIATION WITH AND WITHOUT BEVACIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Conference

Sulman, Erik, Won, Minhee, Ezhilarasan, Ravesanker et al. (2013). A MOLECULAR PREDICTOR OF RESPONSE TO BEVACIZUMAB BASED ON ANALYSIS OF RTOG 0825, A PHASE III TRIAL COMPARING CHEMORADIATION WITH AND WITHOUT BEVACIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA . NEURO-ONCOLOGY, 15 152-152.

International Collaboration

cited authors

  • Sulman, Erik; Won, Minhee; Ezhilarasan, Ravesanker; Sun, Peng; Blumenthal, Deborah; Vogelbaum, Michael; Colman, Howard; Jenkins, Robert; Chakravarti, Arnab; Jeraj, Robert; Brown, Paul; Jaeckle, Kurt; Schiff, David; Dignam, James; Atkins, James; Brachman, David; Werner-Wasik, Maria; Gilbert, Mark; Mehta, Minesh; Aldape, Ken

sustainable development goals

authors

date/time interval

  • November 21, 2013 -

publication date

  • November 1, 2013

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • San Francisco, CA

Conference

  • 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 152

end page

  • 152

volume

  • 15